ຄູ່​ຮ່ວມ​ງານ Qiming Venture ຂອງ Shanghai ລະດົມ​ທຶນ​ໃໝ່ 3.2 ຕື້​ໂດ​ລາ

Qiming Venture Partners, one of the largest venture investment firms to arise in China in the past two decades, has raised $3.2 billion of new investment funds, the Shanghai-headquartered company said in a statement on Monday.

The new money lifts its capital raised since 2006 to $9.6 billion. Early picks include Xiaomi, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, APT Medical, Meituan, Bilibili and Roborock.

Qiming has two members of the 2022 Forbes Midas List – Nisa Leung at No. 61 and Duane Kuang at No. 72. (See related post ທີ່ນີ້.)

Qiming is part of a group of home-grown venture companies that began to take off after China joined the World Trade Organization. It was set up in 2006 in Shanghai by Gary Rieschel, who Leung first met while an intern in California, along with Kuang, who she golfed with back in Silicon Valley, too.

Qiming seized upon an on-the-ground advantage in relatively fast-growing, fast-changing China to invest in more than 70 “unicorn” businesses that have grown to more $1 billion in valuation.

ເບິ່ງຂໍ້ຄວາມທີ່ກ່ຽວຂ້ອງ:

ຈີນ​ເອົາ​ສະມາຊິກ 17 ຄົນ​ລົງ​ໃນ​ບັນຊີ​ລາຍ​ຊື່ Forbes Midas ປີ 2022

ກໍາລັງໃຈຂອງແມ່ເຮັດໃຫ້ນັກລົງທຶນດ້ານສຸຂະພາບຂອງຈີນຢູ່ໃນບັນຊີລາຍຊື່ Forbes Midas

@rflannerychina